NovaBay's first commercial deal for NeutroPhase targets China
This article was originally published in Scrip
Executive Summary
In a sign of the continued rise of China as a priority target for both Big Pharma and development stage companies alike, NovaBay Pharmaceuticals' first commercial partnership for its lead product, the wound healing preparation NeutroPhase (pure hypochlorous acid), is with the Shanghai-based firm Pioneer Pharma.